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Background. The systemic vasculitides are syndromes characterized by inﬂammation and injury (necrosis or thrombosis) of blood
vessels, resulting in clinical manifestations according to the aﬀected vascular bed, but not classically in stocking-glove neuropathy.
Objective. To describe a form of primary vasculitis aﬀecting strictly peripheral nerves manifesting as stocking-glove neuropathy.
Methods. Case series of 110 patients seen in three centers in Bogot´ a who presented with symptoms and signs of polyneuropathy
and/or were identiﬁed with vasculitis aﬀecting only the peripheral nerves, and who underwent sural nerve biopsy. Results.S i x
patients had a vasculitis aﬀecting only the peripheral nerves diagnosed on sural nerve biopsy which demonstrated a mixed
inﬁltrateofmonocytes/macrophagesandlymphocytesespeciallyinthesmallepineurialbloodvessels.Overtime,allhadworsening
of symptoms, with grip weakness and motor deﬁcits in the hand and feet. Serologies and acute phase reactants were normal
in all patients. Treatment response to immunosuppression was satisfactory in 5 patients; 1 patient had progressive neurologic
damage. Conclusions. There is a distinct form of primary vasculitis of the peripheral nervous system characterized by distal sensory
polyneuropathy with stocking-glove distribution with good prognosis, few and minor relapses and good response to treatment
even after delayed diagnosis.
Copyright © 2009 Jos´ eF´ elix Restrepo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Thesystemicvasculitidesareclinicallyheterogeneousentities
characterized by inﬂammation and damage by necrosis or
thrombosis of blood vessels, with clinical manifestations
according to the distribution of the involved vessels [1].
Peripheral neuropathies have associated with or been
attributed to the presence of vasculitis in a variable propor-
tion of patients, including infections, myeloproliferative dis-
orders, and many inﬂammatory conditions. In some series,
up to 75% of peripheral neuropathies occurring in patients
with connective tissue diseases and systemic vasculitis are
due to vasculitis [2, 3]. The peripheral neuropathy of most
of these disorders is usually due to mononeuritis multiplex
or sensorimotor polyneuropathy and can be diﬃcult to
clinically distinguish from other causes.
The purpose of this study is to describe the presence
of a primary vasculitis aﬀecting only the peripheral nerve
and clinically manifesting as a stocking-glove neuropathy, its
clinical course, associated clinical ﬁndings, and discuss its
pathogenesis.
2.MaterialsandMethods
We performed a study of all 110 patients presenting bet-
ween 1993–2004 with symptoms and signs of polyneuropa-
thy or who presented at electromyography (EMG) with
mononeuritis multiplex or distal sensory-motor polyneu-
ropathy suggestive of a primary or secondary vasculitis or
vasculitis strictly conﬁned to the peripheral nerves that
underwent sural nerve biopsy. Demyelinating neuropathies
were excluded.
We employed the following deﬁnitions in establishing
a diagnosis of necrotizing angiopathy of the peripheral
nervous system:
(1) segmental vessel wall necrosis of epineurial vessels,2 International Journal of Rheumatology
(2) inﬂammatory cell inﬁltrates at the level of the
transneurium of the epineurial vessels,
(3) ﬁbrin deposition with or without thrombosis at the
level of the vessels of the epineurium, and in some
cases deposits of hemosiderin easily visible,
(4) recanalization.
We considered the diagnosis if all of the ﬁrst three
criteria were present; criterion 4 may or may not have been
present. Patients were classiﬁed as having lymphomonocytic
vasculitis if there was presence of inﬁltrate composed
mainly of mononuclear cells (monocytes, macrophages and
lymphocytes), especially in arterioles and small sized vessels
[4]. All patients underwent EMG according to a standard
protocol [5].
Neuropathies were classiﬁed as mononeuritis multiplex
(motor and/or sensory deﬁcits in the distribution of one
or more isolated peripheral nerve), distal symmetrical
sensorimotor polyneuropathy (displaying symmetrical distal
stocking-glove distribution of sensory and motor deﬁcits),
or asymmetrical/overlapping neuropathy (motor or sensory
deﬁcits with substantial limb asymmetry) [6].
All patients had a complete blood count (CBC), West-
ergren sedimentation rate, C-reactive protein, rheumatoid
factor (RF), antinuclear antibody (ANA), anti-DNA, anti-
RNP, anti-Ro, anti-La, anti-Smith, c-ANCA, p-ANCA, cre-
atine phosphokinase (CPK), hepatitis B and C serologies,
protein electrophoresis, C3 and C4 complement, glucose,
total cholesterol and lipid proﬁle, triglycerides, creatinine,
AST, ALT, and chest radiograph.
3. Results
Of 110 patients who underwent sural nerve biopsy between
1993 and 2004, a total of 6 were diagnosed with vas-
culitis strictly conﬁned to the peripheral nerves accord-
ing to the criteria above. Five patients had sensorimotor
axonal/demyelinating polyneuropathy and one patient had
mononeuritis multiplex. Onset of symptoms was between 56
and 73 years of age (mean 64.8 years). All six patients were
female. None fulﬁlled American College of Rheumatology or
relevantothercriteriaforconnectivetissuediseasesincluding
systemic lupus erythematosus (SLE) [7], primary Sj¨ ogren
syndrome [8], scleroderma [9], polyarteritis nodosa (PAN)
[10], microscopic polyangiitis, Wegener’s granulomatosis or
Churg-Strauss disease [11]. The other diagnosis included 20
patientswithRA,25SLE,18Sj¨ ogrensyndrome,8polymyosi-
tis, 5 PAN, 3 mixed connective tissue disease, 12 undiﬀer-
entiated connective tissue disease, 2 scleroderma, 1 case of
lepraandthe remainder had no other identiﬁable underlying
disorder including cryoglobulinemia, malignancy, hepatitis
B or C, toxin exposure, diabetes or other metabolic or
nutritional disorders.
3.1. Clinical Aspects. In all 6 cases the clinical picture devel-
oped slowly, with patients developing symptoms between
18 and 38 months before the diagnosis was made. At
disease outset, patients sought attention for paresthesias,
dysesthesias or pain in the hands and feet and symmetric
Figure 1: (Case 4). Medium diameter epineural artery. A promi-
nentlymphocyticinﬂammatoryinﬁltrateispresentinthethickened
vessel wall, with ﬁbrinoid material causing luminal obstruction.
H&E, 40X.
lower extremity muscle weakness. Symptoms were com-
monly thought to represent entrapment neuropathies of
the upper or lower extremities or to represent the start of
the muscle inﬂammation of dermatomyositis/polymyositis
(cases 5 and 6). After 3 to 6 months, signs of neurological
compromise accelerated with worsening pain.
In a second phase of disease, patients presented with grip
strength weakness and motor deﬁcits in the hands and feet
raisingthepossibilityofapolyneuropathy.Thiswasthepoint
at which EMG was obtained.
The average number of months between the onset of
symptoms until EMG diagnosis in the 5 patients with sen-
sorimotor axonal/demyelinating polyneuropathy was 22.4
months and 18 months in the one case of mononeuritis
multiplex. EMG involvement in order of frequency from
high to low was external popliteal sciatic nerve, internal
popliteal-sciatic nerve, sural nerve, median nerve and ulnar
nerve. In the case of mononeuritis multiplex foot drop of the
left foot was present.
The time lapse between the EMG study and the sural
nerve biopsy in the 6 patients was between 45 and 60 days.
The result of the sural nerve biopsy in all 6 patients was
compatible with a monocytic/macrophage and lymphocytic
inﬁltrate especially at the level of the arterioles and small
caliber blood vessels. Findings were of a necrotizing lym-
phomonocytic vasculitis strictly conﬁned to the epineurium
of the peripheral nerves. The average period of observation
after diagnosis was 4 years (range: 2.7 to 8 years), during
which no manifestations suggestive of systemic involvement
or other disease occurred (Figures 1 and 2).
3.2. Laboratory Findings. The Westergren sedimentation
rate (ESR) was modestly elevated in all cases at diagnosis
(between 30 and 40mm/hr; mean 34). ANA was detectable
in two patients in low titer (≤1: 160), and anti-Ro, anti-
La, anti-Smith, ant-RNP, RF, p- and c-ANCA, protein
electrophoresis, C3 and C4 complement and markers of
hepatitis B and C were negative.
The 6 patients have a similar clinical picture with invo-
lvement of the distal nerves consistent with the clinicalInternational Journal of Rheumatology 3
Figure 2: (Case 5). Immunoperoxidase staining with CD20,
demonstrating the great majority of cells to be B lymphocytes,
suggesting a humoral pathophysiologic diathesis. 40X.
and pathological picture of an idiopathic vasculitis strictly
aﬀecting the peripheral nerves of delayed onset (Table 1). A
predominate lymphocytic inﬁltrate was present in the small
and medium sized epineurial arteries (Figure 1). In case
5, immunoperoxidase staining with CD20 demonstrated a
majority of cells to be B lymphocytes (Figure 2).
3.3. Treatment. All patients received treatment with gluco-
corticosteroids at a dose of .5 to 1mg/kilogram/day until
control of symptoms of pain and dysesthesia was achieved.
Thedailycorticosteroiddosewastaperedby5mgeachdayto
30mg a day, and then by 2.5mg each week to a maintenance
dose of 2.5mg daily for one year, and then discontinued.
All patients received concomitant azathioprine at a dose of
100mg a day for two years unless on cyclophosphamide.
Patients 5 and 6 required bolus cyclophosphamide (500
mg/month) over 1 year due to the severity and course of the
disease.Patients5and6weretreatedwithcyclophosphamide
beginning 3–6 months after initiation of therapy because of
poor initial treatment response.
Complete recovery was achieved in 5 patients by 6
months following initiation of treatment; only patient 5 had
a severe course with neurological sequelae. All patients had
quiescent disease during the subsequent 2 years of follow-up.
4. Discussion
We identiﬁed a total of 6 patients with sensorineural
polyneuropathy,withaxonalandmyelindegenerationoccur-
ring in isolation, without associated connective tissue,
metabolic, toxic, degenerative, inﬁltrative, or infectious
disease.
The neuropathy in these cases is distal in nature, with
stocking-glove dysesthesias. Histopathology reveals foci of
lymphomonocytic inﬁltrate. We believe that this necrotizing
angiopathy occurs in isolation, without systemic features, at
the level of the peripheral nerves.
In 1880, Leyden [12] reported on polyneuropathies
of inﬂammatory character occurring in the absence of
a connective tissue disease, infection, toxins, cancers and
other identiﬁable associations. One of these was polyarteritis
nodosa, described as a unique clinical entity in 1866 by
Kussmaul and Maier [13].
In 1972, a group of investigators from the Mayo Clinic
introduced classiﬁcation of angiopathic neuropathy, and
included sural nerve biopsy results in their considerations,
especially in patients with rheumatoid arthritis (RA), pol-
yarteritis nodosa (PAN), and then later other connective
tissue diseases [14]. This opened the door for an improved
pathophysiologic understanding of these conditions. Three
years later, Dyck et al. [15] reported on 53 Mayo Clinic
patients with a diagnosis of chronic inﬂammatory polyneu-
ropathy developing over an average of 7.5 years. They
described the histopathology of the sural nerve in these
cases, noting a mononuclear cell inﬁltrated suggestive of
an inﬂammatory process, and concluded that these patients
did not have vasculitis, but rather a nonvasculitic chronic
inﬂammatory condition.
Other reports of isolated necrotizing angiopathy have
includedthoseofKisseletal.[6](7patients),andagainDyck
etal.[16]whodescribedafurther20patientswithperipheral
nerve involvement, including 5 with deﬁnite vasculitis and
15 with a vasculopathy. The average length of evolution of
symptoms was 11.5 years. This publication served to sharpen
the concept of nonsystemic vasculitic neuropathy. Dyck
concluded that peripheral neuropathy can occur secondary
to a necrotizing angiopathy, and in some cases can be
associated with a connective tissue disease, but can also be
due to an isolated angiitis of the peripheral nervous system.
Peripheral nerve disease may be asymmetric and involve
the muscle, sometimes with an aggressive and chronically
relapsing clinical course [17–21]. Biopsies may demonstrate
perivascular inﬁltrate; in one report, 76% of cases had
involvement of the peripheral nerves and muscles, sup-
porting the concept of isolated vasculitis of the peripheral
nervous system [22].
Immunoglobulin deposits and C3 may be detected in a
substantial number of specimens [21]. Acute phase reactants
are elevated in 20%–65% of reported cases [18–21]. In our
cohort the ESR was only moderately elevated, with a median
of 34mm/1hr.
Sural nerve biopsy has become an important diagnostic
procedure for evaluation of vasculitis since its introduction
in 1975. Like others, we have made increasing use of this
technique. Of the 6 cases reported here, 1 was of the 21
patients studied in 1992 who had isolated peripheral nerve
involvement [1]. This patient served as our index case and
led us to our observations in the subsequent 12 years.
All of our patients received treatment with glucocorti-
costeroids ad moderate doses and azathioprine with good
clinicalresponse,basedonthecompletecontrolofsymptoms
and the normalization of the EMG ﬁndings, except for the
5th and 6th patients who received bolus cyclophosphamide
because of rapid clinical deterioration. Patient 6 remains
without symptoms or sequelae 2 year following this treat-
ment. The relatively rapid response to treatment despite the
delayed diagnosis suggests that there is persistent low grade
inﬂammation possibly at the level of the epineurium, with4 International Journal of Rheumatology
Table 1: Idiopathic vasculitis strictly aﬀecting the peripheral nerves.
Patient Age(years) Clinical aspects
Time between
symptom onset
and diagnosis
(months)
Sural nerve biopsy
ﬁndings Comments
Durationoffollow-
up after diagnosis
(years)
16 3
Dysesthesias
and paresthesias
in the hands and
feet
38 Lymphomonocytic
vasculitis —8
26 5Paresthesias in
hands and feet 18
Necrotizing
Lymphomonocytic
vasculitis
—3 . 5
36 8
Dysesthesias
and paresthesias
in the hands and
feet
23 Lymphomonocytic
vasculitis —4
46 4
Paresthesias in
the hands and
feet
27
Necrotizing
Lymphomonocytic
vasculitis
—2 . 6
57 3Paresthesias and
left foot drop 18
Necrotizing
Lymphomonocytic
vasculitis
ANA 1 : 160;
no evidence of
SLE or SS
3
65 6
Dysesthesias
and paresthesias
in both lower
extremities
6
Necrotizing
Lymphomonocytic
vasculitis
ESR 40mm/hr
ANA 1 : 80
No evidence of
SLE, SS, RA
3
ESR: erythrocyte sedimentation rate; ANA: antinuclear antibody; SLE: systemic lupus erythematosus; SS: Sj¨ ogren syndrome; RA: rheumatoid arthritis.
the import that isolated peripheral nervous system vasculitis
is a clinically more indolent and benign disorder than PAN
and other forms of vasculitis.
Of particular note is the presence of CD20 positive (B-
cell) lymphocytes in case 5. These cells are generally not
described as a prominent feature of systemic or localized
vasculitis, but suggest a possible role for them in the patho-
genesis of vasculitis which requires further investigation.
This patient has not developed a malignancy, including B-
cell lymphoma, during the follow-up period.
The histological pattern in the 6 patients is characterized
byalymphomonocyticinﬁltrateaﬀectingthesmallarterioles
of the vasonervorum of the distal peripheral nerves of the
hands and feet and absence of polymorphonuclear cells,
which can be mild, moderate or severe and signiﬁcant
endothelialthickening.Also4outofthesamplehasnecrotiz-
ingvasculitis.Theclinicalcourseofthese6patientsissimilar,
with no systemic disease and virtually no laboratory abnor-
malities. It is possible that lymphocytic inﬁltration seen on
biopsy is a late feature of the arteritis, disease, but this is dif-
ﬁcult to assess because in virtually all cases, biopsies are per-
formed after the disease has been established for some time.
Finally, we believe that there is a primary angiitis of the
peripheral nervous system, that may present in one of two
forms. One is the well deﬁned arteritis and distal asymmetric
polyneuropathy which can cause muscle involvement with
an aggressive course with relapses in 38% of cases, increased
acute phase reactants and which can occasionally be fatal
[15]. The other is a distal sensory polyneuropathy with
stocking-glove distribution with good prognosis, few and
minor relapses, and good response to treatment, like the
cases we have presented in this article.
No randomized clinical controlled trial of therapy has
been done in patients with nonsystemic vasculitis neuropa-
thy [23], but the majorities of retrospective data support
the use of glucocorticoid and immunosuppressive. In refrac-
tory cases, it has been used intravenous immunoglobulin,
mycophenolate,rituximab,inﬂiximab,oralemtuzumab[24].
We suggest that patients with a polyneuropathy without
apparent underlying disease should be suspected of having
an isolated vasculitis of the peripheral nervous system. These
patients should undergo diagnostic evaluation including
EMG and measurement of acute phase reactants, and
in appropriate cases (sural) nerve biopsy. Even after a
protracted clinical course, the symptoms may respond to
treatment with glucocorticosteroids and/or other immuno-
suppressive therapies.
Limitations from our study are the small sample size. In
addition, because this is a case series report, the improve-
ment of patient was based in the clinical observation and
criteria by the treating physician, however, improvement
was documented objectively by EMG in all patients. Larger
samples and case controlled studies are needed to conﬁrm
our ﬁndings.
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